The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?
Pfizer/Biohaven Is Only $10bn-Plus M&A In First Half
INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. In Vivo's sister publication Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.
You may also be interested in...
Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.
Aldeyra’s bid to rely on a single Phase III trial after an initial one failed is rejected by FDA, but firm already has a special protocol assessment under review for a trial that could provide the symptom data it says agency needs to approve the RASP modulator in dry eye.
Aldeyra already has a special protocol assessment under review at the FDA for a trial to provide the symptom data the agency said is needed for approval of the RASP modulator in dry eye disease.